Volume 11,Issue 5
Research Progress in Integrative Chinese and Western Medicine Treatment and Molecular Mechanism of Helicobacter Pylori-Associated Chronic Atrophic Gastritis
Chronic atrophic gastritis (CAG) is a critical intermediate stage in the gastric mucosal inflammation-to-carcinogenesis cascade, with Helicobacter pylori (H.pylori) infection as its primary pathogenic driver. Confronted with rising antibiotic resistance of standard Western eradication regimens and limited efficacy in reversing advanced mucosal atrophy and intestinal metaplasia, this review systematically explores the pathogenic mechanisms of H. pylori-associated CAG and the diagnostic and therapeutic value of integrated traditional Chinese and Western medicine (ITCWM). We analyzed H. pylori molecular pathogenesis, summarized updated Western eradication regimens, interpreted the core of the 2025 Expert Consensus on CAG ITCWM diagnosis and treatment, and synthesized high-level clinical evidence of ITCWM. H. pylori mediates mucosal lesions via virulence factors that hijack signaling and drive epigenetic remodeling. High-dose dual therapy with a potassium-competitive acid blocker (P-CAB) provides an 89%–95% eradication rate and fewer adverse events. ITCWM enhances eradication success, while agents such as Weifuchun can reverse mucosal atrophy and low-grade dysplasia via multi-target actions. ITCWM provides an effective full-cycle management strategy for H. pylori -associated CAG, and its combination with regenerative medicine may further halt the gastric malignant transformation.
[1] Integrative Medicine, 2025, Expert Consensus on the Diagnosis and Treatment of Chronic Non-Atrophic Gastritis with Integrated Traditional Chinese and Western Medicine (2025 Edition). Chinese Journal of Integrated Traditional and Western Medicine on Digestion, 33(12): 1123–1140.
[2] Fang J, Du Y, Liu W, et al., 2023, Chinese Guidelines for the Diagnosis and Treatment of Chronic Gastritis (2022, Shanghai). Chinese Journal of Gastroenterology, 28(3): 149–180.
[3] Professional Committee of Digestive System Diseases, Chinese Association of Integrative Medicine, 2025, Expert Consensus on the Diagnosis and Treatment of Chronic Atrophic Gastritis with Integrated Traditional Chinese and Western Medicine (2025 Edition). Chinese Journal of Integrated Traditional and Western Medicine on Digestion, 33(3): 230–241.
[4] Zhang M, Li J, Wang Z, 2024, Advances in Research on Helicobacter pylori Virulence Factors CagA and VacA and Gastric Mucosal Lesions. Chinese Journal of Integrated Traditional and Western Medicine on Digestion, 32(8): 635–639.
[5] Raza Y, Li J, Ahmed S, et al., 2025, Update on Molecular Pathogenesis of Helicobacter pylori-Induced Gastric Cancer. World Journal of Gastrointestinal Pathophysiology, 16(2): 107052.
[6] Zhang J, Wang W, Yan S, et al., 2022, CagA and VacA Inhibit Autophagy of Gastric Mucosal Epithelial Cells and Aggravate Gastric Precancerous Lesions. Journal of Central South University (Medical Sciences), 47(7): 942–952.
[7] Fang Y, Liu S, Li J, et al., 2021, Inflammation-Associated Senescence Promotes Helicobacter pylori-Induced Atrophic Gastritis. Cellular and Molecular Gastroenterology and Hepatology, 11(3): 857–880.
[8] Wu X, Zhu H, Hu Y, et al., 2025, Meta-Analysis of Helicobacter pylori and the Gut Microbiome Interactions and Clinical Outcomes. Frontiers in Cellular and Infection Microbiology, 15: 1610523.
[9] Megraud F, Bruyndonckx R, Coenen S, et al., 2021, Helicobacter pylori Resistance to Antibiotics in Europe in 2018 and Its Relationship to Antibiotic Consumption in the Community. Gut, 70(10): 1815–1822.
[10] Liu W, Xie Y, Lu H, et al., 2018, Fifth Chinese National Consensus Report on the Management of Helicobacter pylori Infection. Helicobacter, 23(2): e12475.
[11] Lin A, Lin Z, Liu Y, et al., 2024, Ten-Day Versus 14-Day Vonoprazan–Amoxicillin High-Dose Dual Therapy for Helicobacter pylori Eradication in China: A Multicenter, Open-Label, Randomized Study. Journal of Gastroenterology and Hepatology, 39(12): 2645–2653.
[12] Liu T, Zheng S, Yang J, et al., 2024, Efficacy and Safety of Vonoprazan Plus Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Meta-Analysis. Journal of Hainan Medical University, 30(16): 1259–1265.
[13] Lee J, Jeon S, Lee H, et al., 2022, Rebamipide for the Improvement of Gastric Atrophy and Intestinal Metaplasia: A Prospective, Randomized, Pilot Study. Digestive Diseases and Sciences, 67(6): 2395–2402.
[14] Cheng X, Gu H, Chong Y, et al., 2025, Vitamin C Mediates IGFBP7 to Alleviate Chronic Atrophic Gastritis via the HIF-1α/VEGF Pathway. Journal of Cellular and Molecular Medicine, 29(4): e70392.
[15] Li H, Li J, Lai M, 2025, Efficacy Analysis of Folic Acid in Chronic Atrophic Gastritis with Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. BMC Gastroenterology, 25(1): 69.
[16] Yang G, Feng S, Liu J, et al., 2025, The Second Beijing Consensus on Holistic Integrative Medicine for the Management of Helicobacter pylori-Associated Disease Syndrome. Cancer Screening and Prevention, 4(2): 67–78.
[17] Li J, Liu Z, Han X, 2023, Expert Consensus on Clinical Application of Weifuchun in the Treatment of Precancerous Lesions of Atrophic Gastritis. Journal of Traditional Chinese Medicine, 64(2): 212–216.
[18] Wang L, Ding X, Li P, et al., 2023, Efficacy and Safety of Weifuchun Tablet for Chronic Atrophic Gastritis: A Systematic Review and Meta-Analysis. PLOS ONE, 18(4): e0284411.
[19] Zou T, Gao Q, Liu S, et al., 2024, Effectiveness and Safety of Moluodan in the Treatment of Precancerous Lesions of Gastric Cancer: A Randomized Clinical Trial. Journal of Digestive Diseases, 25(12): 784–794.
[20] Xie D, Wu C, Wang D, et al., 2024, Weifuchun Tablet Halted Gastric Intestinal Metaplasia and Dysplasia Associated with Inflammation by Regulating the NF-κB Pathway. Journal of Ethnopharmacology, 318(Pt B): 117020.
[21] Liu Q, Tang J, Chen S, et al., 2022, Berberine for Gastric Cancer Prevention and Treatment: Multi-Step Actions on the Correa’s Cascade Underlie Its Therapeutic Effects. Pharmacological Research, 184: 106440.